Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa11/27/2018
Constant Pharmaceuticals will begin development of an oral formulation of TXA127 for treatment of RDEB. In animal and in vitro models, TXA127 has demonstrated anti-fibrotic effects and caused reduction in the fusion of digits. After the development stage, Constant aims to open a Phase 2 trial of TXA127 in Europe and the United States. EBRP is a proud funder of this research.
Comments are closed.
|
|
|
|
|
|
|
|
